Drug profile · INN
cabozantinib s-malate
CABOMETYX
cabozantinib s-malate (CABOMETYX) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — cabozantinib s-malate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
cabozantinib s-malate (CABOMETYX) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: Hepatocyte growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cabozantinib s-malate?
cabozantinib s-malate (CABOMETYX) is a hepatocyte growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cabozantinib s-malate?
CABOMETYX is a marketed brand name for cabozantinib s-malate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cabozantinib s-malate?
cabozantinib s-malate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.